Thu, Aug 28, 2014, 8:23 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Supernus Pharmaceuticals, Inc. (SUPN) Message Board

  • alamjob239 alamjob239 Jul 7, 2014 5:45 PM Flag

    Supn Lawsuit It is clear Court will not block Ranbaxy's filing of an ANDA to manufacture a generic version of Shire's Intuniv®

    Shire LLC et al. v. Ranbaxy Inc. et al.
    1:14-cv-00827; filed June 25, 2014 in the District Court of Delaware

    • Plaintiffs: Shire LLC; Shire Development LLC; Supernus Pharmaceuticals Inc.
    • Defendants: Ranbaxy Inc.; Ohm Laboratories Inc.; Ranbaxy Laboratories Ltd.

    Infringement of U.S. Patent Nos. 6,287,599 ("Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles," issued September 11, 2001) and 6,811,794 (same title, issued November 2, 2004) based on Ranbaxy's filing of an ANDA to manufacture a generic version of Shire's Intuniv® (guanfacine, used to treat attention-deficit hyperactivity disorder). View the complaint here.

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SUPN
8.81-0.15(-1.67%)Aug 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.